Metrics as of 10/15/2026, 11:23 PM (Berlin time), refresh in progress.
China Pharma Holdings, Inc.
China Pharma Holdings, Inc. (CPHI) specializes in the development, manufacturing, and marketing of both generic and branded pharmaceutical as well as biochemical products. The company primarily caters to hospitals and independent retailers throughout mainland China. Its comprehensive product portfolio encompasses…
1D
-2.8%
1W
-27.1%
1M
-4.3%
6M
+6.2%
YTD
-42.2%
1Y
-63.2%
2Y
-70.1%
5Y
-99.7%
10Y
-99.3%
Next earnings date
No date known
Volatility around earnings
~8% stronger price swings than usual
P/E
-0.69
P/B
0.08
EV/EBITDA
-25.33
RETURN ON EQUITY
-4.0%
NET MARGIN
-153.8%
DEBT/EQUITY
0.1
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
93.8%
FLOAT SHARES
40,340,611
AVG. DAILY VOLUME (30D)
3,231,518
China Pharma Holdings, Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in China.
The CEO is Zhilin Li, the company employs around 215 people.
The IPO was on 17/04/2002; the stock trades on AMEX under the ticker CPHI.
Around past earnings, price swings were roughly 8% stronger than usual.
No, China Pharma Holdings currently does not pay a dividend.
Comparable stocks include Merck, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Zoetis, Sandoz Group, Viatris, Lantheus Holdings and Amneal Pharmaceuticals.
Clicking "Analyze stock" lets five strategies assess China Pharma Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.